Doximity, Inc.
DOCS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.30 | -3.57 | -2.50 | 0.50 |
| FCF Yield | 0.64% | 0.52% | 0.89% | 0.63% |
| EV / EBITDA | 185.46 | 170.38 | 208.38 | 119.16 |
| Quality | ||||
| ROIC | 4.84% | 4.33% | 4.38% | 6.32% |
| Gross Margin | 90.25% | 89.18% | 89.54% | 91.59% |
| Cash Conversion Ratio | 1.51 | 1.16 | 1.58 | 0.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.49% | 10.51% | 10.82% | 11.05% |
| Free Cash Flow Growth | 56.22% | -37.99% | 52.92% | -5.07% |
| Safety | ||||
| Net Debt / EBITDA | -2.02 | -1.87 | -3.83 | -1.84 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 44.99 | 76.20 | 75.10 | 63.02 |